Notified bodies join chorus of criticism of proposed European AI regs

Team-NB has come out strongly against the regulation, arguing it will add to administrative burdens, reduce notified body capacity and create confusion.

By Nick Paul Taylor • Oct. 26, 2021

Zimmer, J&J chase Stryker's lead in ortho robotics

"I don't think it's a market share battle as much as market expansion. All the companies are riding this wave," said Needham & Co. analyst Mike Matson.

By Susan Kelly • Oct. 25, 2021

Explore the Trendline➔

Top 5 stories from MedTech Dive

From haphazard layoffs at the Food and Drug Administration to the industry’s current IPO environment and tracking FDA-authorized AI devices, here is a collection of top stories from MedTech Dive.

By MedTech Dive staff

Roche's refillable eye implant becomes Eylea's latest threat

The FDA has approved Susvimo, a device that continuously administers a version of Roche's Lucentis over several months. It could challenge Regeneron's top-selling drug.

By Ben Fidler • Oct. 25, 2021

EU task force calls for MDR legacy device surveillance requirements

The Medical Device Coordination Group said legacy devices are subject to rules on post-market surveillance, market surveillance and vigilance. Manufacturers need to create and maintain periodic safety update reports.

By Nick Paul Taylor • Oct. 25, 2021

Amazon teases 5 more cities to get virtual Amazon Care offering this year

Amazon Care is currently live in the Washington, D.C. and Baltimore area, and will be rolled out in Dallas, Chicago, Philadelphia, Boston and Los Angeles this year, the unit's director told the HLTH conference this week.

By Rebecca Pifer • Oct. 22, 2021

Tenet sees widespread volume recovery, again raises forecast

Despite the operating challenges poised by COVID-19 in the third quarter, the for-profit health system was able to manage through the headwinds, executives said Thursday during a call with investors. 

By Samantha Liss • Oct. 22, 2021

Abbott, Intuitive, J&J set tone for earnings: Testing up, procedures down

The medtechs in recent days confirmed the mixed financial impact of the delta wave and early signs of recovery in elective procedures in the U.S. Reports from Boston Scientific and Stryker come next week.

By Nick Paul Taylor • Oct. 21, 2021

Medtronic surgical robotics head talks Hugo, taking on Intuitive, COVID-19 challenges

Megan Rosengarten spoke to MedTech Dive about challenging Intuitive Surgical's 20-year lead in soft tissue robotics, growing global robotics usage and the stress of entering a new market amid COVID-19.

By Ricky Zipp • Oct. 20, 2021

Abbott COVID-19 sales rebound, but calls market too volatile for 2022 forecast

CEO Robert Ford warned investors that despite a big uptick driven by the delta surge, "we'll have to update on a rolling quarterly basis."    

By Greg Slabodkin • Oct. 20, 2021

Intuitive says delta variant slows Q3 da Vinci procedure growth

The robot-assisted surgery leader said the latest wave of COVID-19 cases curbed demand for non-emergency surgeries, especially in the U.S. South in states with low vaccination rates. 

By Susan Kelly • Oct. 20, 2021

In last ditch plea to save MCIT, medtech groups suggest fixes to CMS

AdvaMed and MDMA responded to a call for feedback on the planned repeal of the Medicare Coverage of Innovative Technology pathway by proposing tweaks and new ideas to salvage it.

By Nick Paul Taylor • Oct. 20, 2021

Over-the-counter hearing aids proposed by FDA

A Cowen analyst said the policy change would allow consumer electronics manufacturers to get into the lucrative hearing aid market that has been dominated by ReSound, Sonova and William Demant. 

By Greg Slabodkin • Oct. 19, 2021

J&J delays Ottava robot rollout as global medtech business boosts Q3 sales

The healthcare giant was the first procedure-dependent medtech to announce earnings this quarter, potentially foreshadowing what others in the industry will report in the coming weeks.

By Ricky Zipp • Oct. 19, 2021

Philips sees sleep business recovering from recall in H2 2022, analysts doubtful

William Blair analysts warn that limited provider support during the medtech's recall is hurting brand credibility and impacting Philips' ability to regain market share, while positioning ResMed as the beneficiary of "durable" share loss. 

By Greg Slabodkin • Updated Oct. 22, 2021

Medtronic misses bid for early FDA OK in renal denervation, stock slides

The independent data safety monitoring board found the clinical trial needs to keep enrolling patients and gather results to show if the treatment works.

By Nick Paul Taylor • Oct. 18, 2021

Anatomy of a medical device recall: How defective products can slip through an outdated system

"It truly is like we are operating in about the 1950s," one consultant noted of the process. The FDA has held two meetings in the past year to mull improvements.

By Ricky Zipp • Oct. 18, 2021

Medtechs need strategy to prevent bias in AI-machine learning-based devices: FDA

The agency is mulling the types of information medtechs might include in labeling for such devices to support transparency. A Philips rep cautioned about the pitfalls of "information overload."

By Greg Slabodkin • Oct. 15, 2021

Biden circling former FDA chief Califf to again lead agency: report

The Washington Post reported the administration was "closing in" on the choice, citing unnamed sources. Still, the White House declined to comment and Califf could face opposition from Senate Democrats.

By Ricky Zipp • Oct. 15, 2021

Medtronic pledges R&D boost, brand refresh, amid rising Big Tech rivalry

CEO Geoff Martha said the device giant is still "building out that direct-to-consumer muscle" and acknowledged "healthy competition" with the likes of Apple and Google.

By Greg Slabodkin • Oct. 14, 2021

EU proposes to delay IVD Medical Device Regulation, citing COVID-19 backlog

Originally set to go into effect in May 2022, a progressive rollout is now planned. The proposal will now go to the European Parliament and Council for adoption, according to the announcement.

By Kim Dixon • Updated Oct. 14, 2021

Boston Scientific, Sterigenics potential targets of EPA ethylene oxide reporting requirements

The agency has written to the operators of 31 medical device sterilization facilities, outlining its plans and requesting information to inform its final decision.

By Nick Paul Taylor • Oct. 14, 2021

Abbott, Dexcom could benefit from CGM use jump among Type 2 diabetes patients: report

The population could drive the next wave of demand for devices to track and control diabetes, Jefferies analysts predict, based on polling of roughly 50 endocrinologists and general practitioners.

By Susan Kelly • Oct. 13, 2021

Withings gets FDA nod for AFib-detecting wearable, taking on Apple

The device, which is capable of detecting atrial fibrillation, combines an analog watch face with health features found in digital smartwatches. The French company joins Apple, Fitbit and Samsung in a crowded market.

By Nick Paul Taylor • Oct. 13, 2021

FDA breakthrough nods go to liquid biopsies for Alzheimer's, cancer drug response

The agency gave the designation to Quanterix's blood test, which has the potential to aid evaluation of people who present with cognitive impairment, and Nonagen Bioscience's non-invasive bladder cancer test.

By Nick Paul Taylor • Oct. 12, 2021

European Commission adds 2 modules to delayed Eudamed database, with no follow-on timeline

Sections on UDI/device registration, and Certificates and Notified Bodies are now available for voluntary use but some features are missing.

By Nick Paul Taylor • Oct. 12, 2021